source
- Alnylam alumni lead RNAi biotech City Therapeutics to IPO filingBiotechs are rushing into the IPO queue. City Therapeutics submitted its public pitch late Thursday, the same night ADARx Pharmaceuticals priced its $446 million Nasdaq debut. Kendall Square-based ...Endpoints · 26d ago↗ source
- FDA advisory panel finds Grail's Galleri multicancer blood test benefits outweigh risksA Food and Drug Administration advisory panel voted 7-2, with one abstention, to conclude that the probable benefits of Grail's Galleri multicancer blood test outweigh its risks. The panel unanimou…